Filters: Keyword is Buprenorphine [Clear All Filters]
"Additional explanation for lack of pharmacodynamic interaction between atazanavir and buprenorphine reported by Vergara-Rodriquez et al." Journal of acquired immune deficiency syndromes (1999) 58, no. 4 (2011): e112; author reply e112-3.
"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial." Archives of general psychiatry 68, no. 12 (2011): 1238-46. Abstract
"Assessing social risks prior to commencement of a clinical trial: due diligence or ethical inflation?" The American journal of bioethics : AJOB 9, no. 11 (2009): 48-54. Abstract
"The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 19, no. 1 (2010): 53-8. Abstract
"Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence." The American journal of drug and alcohol abuse 33, no. 5 (2007): 643-54. Abstract
"The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S7-13. Abstract
"Buprenorphine and HIV primary care: new opportunities for integrated treatment." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S169-72. Abstract
"Buprenorphine for office-based practice: consensus conference overview." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 13 Suppl 1 (2004): S1-7. Abstract
"Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms." Journal of substance abuse treatment 29, no. 4 (2005): 307-12. Abstract
"Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors." Journal of substance abuse treatment 35, no. 1 (2008): 87-92. Abstract
"Buprenorphine: effective treatment of opioid addiction starts in the office." American family physician 73, no. 9 (2006): 1513-4.
"Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 41, no. 6 (2005): 891-6. Abstract
"Case series of buprenorphine injectors in Kuala Lumpur, Malaysia." The American journal of drug and alcohol abuse 34, no. 4 (2008): 511-7. Abstract
"Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases." The American journal of drug and alcohol abuse 33, no. 6 (2007): 869-74. Abstract
"Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial." Annals of internal medicine 152, no. 11 (2010): 704-11. Abstract
"Comparison of tuberculin skin testing reactivity in opioid-dependent patients seeking treatment with methadone versus buprenorphine: policy implications for tuberculosis screening." The American journal of drug and alcohol abuse 35, no. 6 (2009): 439-44. Abstract
"Consensus statement on office-based treatment of opioid dependence using buprenorphine." Journal of substance abuse treatment 27, no. 2 (2004): 153-9. Abstract
"Coordination of medical care and opioid dependence treatment in primary care: a case report." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 24, no. 1 (2003): 43-6.
"Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients." Drug and alcohol dependence 99, no. 1-3 (2009): 132-40. Abstract
"The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S76-82. Abstract
"Cost-effectiveness of buprenorphine and naltrexone treatments for heroin dependence in Malaysia." PloS one 7, no. 12 (2012): e50673. Abstract
"Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study." Journal of addiction medicine 6, no. 3 (2012): 205-11. Abstract
"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence." The New England journal of medicine 355, no. 4 (2006): 365-74. Abstract
"Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users." Addiction (Abingdon, England) 100, no. 2 (2005): 150-8. Abstract
"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 19, no. 1 (2010): 4-16. Abstract
"Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S33-8. Abstract
"Effect of incarceration history on outcomes of primary care office-based buprenorphine/naloxone." Journal of general internal medicine 25, no. 7 (2010): 670-4. Abstract
"Evaluation of a combined online and in person training in the use of buprenorphine." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 27, no. 3 (2006): 39-45. Abstract
"Factors affecting willingness to provide buprenorphine treatment." Journal of substance abuse treatment 36, no. 3 (2009): 244-51. Abstract
"Faculty development in small-group teaching skills associated with a training course on office-based treatment of opioid dependence." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 25, no. 4 (2004): 35-40. Abstract
"Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females." The pharmacogenomics journal 14, no. 3 (2014): 303-8. Abstract
"Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S62-7. Abstract
"Heroin dependence and HIV infection in Malaysia." Drug and alcohol dependence 82 Suppl 1 (2006): S39-42. Abstract
"HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment." Journal of addiction medicine 7, no. 6 (2013): 410-6. Abstract
"HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications." The International journal on drug policy 18, no. 4 (2007): 326-8. Abstract
"HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S22-32. Abstract
"Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians." Journal of addiction medicine 6, no. 2 (2012): 159-65. Abstract
"The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S54-61. Abstract
"Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment." Journal of urban health : bulletin of the New York Academy of Medicine 87, no. 4 (2010): 592-602. Abstract
"Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S39-45. Abstract
"Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S83-90. Abstract
"Initial strategies for integrating buprenorphine into HIV care settings in the United States." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S191-6. Abstract
"Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes." Drug and alcohol dependence 131, no. 1-2 (2013): 127-35. Abstract
"Integrating buprenorphine treatment into office-based practice: a qualitative study." Journal of general internal medicine 24, no. 2 (2009): 218-25. Abstract
"Integration of buprenorphine for substance-abuse treatment by HIV care providers." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S1-2.
"Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S68-75. Abstract
"Interaction between buprenorphine and atazanavir or atazanavir/ritonavir." Drug and alcohol dependence 91, no. 2-3 (2007): 269-78. Abstract
"Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S224-34. Abstract
"Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S235-46. Abstract
"Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market." The American journal of drug and alcohol abuse 35, no. 2 (2009): 68-72. Abstract
